We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Alois Alzheimer
- The amyloid plaque
- Amyloid congophilic angiopathy (ACA)
- Impact of delaying onset of AD
- Impact of delayed onset on prevalence of AD
- The amyloidocentric theory of AD
- Alzheimer's disease - some hard facts
- Alzheimer's disease - some soft facts
- Compelling evidence for the Abeta theory of AD
- Attempting to modify AD and delay its onset
- Optional targets for a disease-modifying drug
- APP structure and domains
- Conformation of APP dimers
- Iron-export ferroxidase activity of APP
- FAD APP mutations cluster sites
- Age at onset correlates with Abeta isoforms
- Reconstituting gamma-secretase activity
- Activation of PS1
- Discovering the oligomers of Abeta
- Abeta amyloid
- P3 oligomer crystal structure (1)
- P3 oligomer crystal structure (2)
- P3 oligomer crystal structure (3)
- P3 oligomer crystal structure (4)
- Abeta pleotropic high-affinity Cu-II binding sites
- The mechanism of neurodegeneration
- The physical state of Abeta amyloid
- Current working model of Abeta toxicity
- Soluble/insoluble Abeta: SDS-resistant oligomers
- Abeta doesn't aggregate in the absence of metals
- Abeta metal binding modes
- Abeta insertion into membrane - a model
- Hydrogen peroxide generation by beta-amyloid
- H2O2 required to generate Abeta oligomers
- Abeta binds to lipid headgroups
- Synapse binding of Abeta pivotal for toxicity
- Detecting Abeta species binding to lipids
- Annexin inhibition of Abeta-lipid binding
- Toxicity of L- and D-Abeta42
- Cell binding of L- and D-Abeta42
- Annexin V inhibits cell binding of L-Abeta
- Abeta - current model
- Model - MPAC with moderate affinity for metals
- Clioquinol (CQ, PBT1) the prototypic MPAC
- Clioquinol prevents Cu(II) interaction with Abeta
- Effect of MPAC (CQ) on Abeta load
- CQex ADAS-cog change from baseline
- PBT2: SAR based on rational drug design
- PBT2 is equal to or better than CQ
- PBT2 inhibits oxidative oligomerization of Abeta
- Effect of PBT2 on interstitial Abeta levels
- Effect of PBT2 on Abeta inhibition of LTP
- Effect of PBT2 on CA1 dendritic spine density
- Functional effect of PBT2 on APP/PS1 mice
- PBT2 reduces Abeta species in the brain
- Short-term PBT2 treatment of female APP/PS1
- PBT2 increases synaptophysin levels in mice
- CQ (PBT1) vs. PBT2
- Study of PBT2-multicentered, placebo-controlled
- Effect of PBT2 on levels of biomarkers
- PBT2 effect on the change from pretreatment
- AD Abeta-directed therapeutics - drugs
- AD Abeta-directed therapeutics - biologics
- Phase II results of potential Abeta targeting drugs
- Phase II results of 'failed' Abeta targeting drugs
- Platinum complexes
Topics Covered
- The amyloid plaque
- Impact of delaying onset of AD
- The amyloidocentric theory of Alzheimer's disease
- Compelling evidence for the Abeta theory of AD
- Delay onset of AD by 5 years
- The best target for a disease-modifying drug
- APP structure and domains
- Iron-export ferroxidase activity of beta-amyloid precursor protein
- Age at onset correlates with Abeta isoforms
- Activation of PS1
- Abeta amyloid
- The mechanism of neurodegeneration
- Abeta metal binding modes
- Current working model of Abeta toxicity
- Abeta amyloid protein: current model consistent with EXAFS
- Metal-protein attenuating compound (MPAC) with moderate affinity for metals
- Clioquinol (CQ, PBT1) the prototypic MPAC
- PBT2: SAR based on rational drug design
- CQ (PBT1) vs. PBT2
- Alzheimer's disease Abeta-directed therapeutics in clinical development: drugs and biologics
- Phase II results of Abeta targeting AD modifying drugs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Masters, C.L. (2011, October 27). Abeta toxicity 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/ALGR6422.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Colin L. Masters has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.